---
title: "Unicycive Therapeutics (UNCY) Gets a Buy from Maxim Group"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292590370.md"
description: "Maxim Group analyst Jason McCarthy reiterated a Buy rating on Unicycive Therapeutics (UNCY) with a $30 price target, noting the stock closed at $5.26. The broader analyst consensus for UNCY is Strong Buy with an average target of $36.71. Additionally, Benchmark Co. maintained a Buy rating with a $13 target. TipRanks also launched a new ETF, RANK, tracking its US Momentum Analysts Index."
datetime: "2026-07-14T08:25:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292590370.md)
  - [en](https://longbridge.com/en/news/292590370.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292590370.md)
generator: "portal-rs"
---

# Unicycive Therapeutics (UNCY) Gets a Buy from Maxim Group

Maxim Group analyst Jason McCarthy reiterated a Buy rating on Unicycive Therapeutics on July 9 and set a price target of $30.00. The company’s shares closed yesterday at $5.26.

### TipRanks Welcomes a New ETF – NYSE:RANK

-   TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
-   RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

McCarthy covers the Healthcare sector, focusing on stocks such as Atossa Therapeutics, Inmune Bio, and AIM ImmunoTech. According to TipRanks, McCarthy has an average return of -11.1% and a 33.07% success rate on recommended stocks. 

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Unicycive Therapeutics with a $36.71 average price target, a 597.91% upside from current levels. In a report released on July 1, Benchmark Co. also maintained a Buy rating on the stock with a $13.00 price target.

### Related Stocks

- [UNCY.US](https://longbridge.com/en/quote/UNCY.US.md)
- [RANK.US](https://longbridge.com/en/quote/RANK.US.md)
- [ATOS.US](https://longbridge.com/en/quote/ATOS.US.md)
- [INMB.US](https://longbridge.com/en/quote/INMB.US.md)
- [AIM.US](https://longbridge.com/en/quote/AIM.US.md)
- [AIMID.US](https://longbridge.com/en/quote/AIMID.US.md)
- [AIMI.US](https://longbridge.com/en/quote/AIMI.US.md)

## Related News & Research

- [Analyst Reaffirms Buy Rating on Unicycive, Maintaining 12-Month Price Target at $30 After FDA Procedural Setback](https://longbridge.com/en/news/296255704.md)
- [Unicycive Therapeutics posts corporate presentation on kidney disease drug pipeline, led by OLC for dialysis hyperphosphatemia](https://longbridge.com/en/news/296044732.md)
- [Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update](https://longbridge.com/en/news/295797130.md)
- [Unicycive Therapeutics Reports Preliminary Q2 2026 Cash Position](https://longbridge.com/en/news/291569499.md)
- [Citizens Jmp Reaffirms "Market Outperform" Rating for Allogene Therapeutics (NASDAQ:ALLO)](https://longbridge.com/en/news/296112335.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**